Multiformin-Type Azaphilones Prevent SARS-CoV-2 Binding to ACE2 Receptor

Protein microarray screenings identified fungal natural products from the azaphilone family as potent inhibitors of SARS-CoV-2 spike protein binding to host ACE2 receptors. Cohaerin F, as the most potent substance from the cohaerin group, led to more than 50% less binding of ACE2 and SARS-CoV-2 spike protein. A survey for structurally related azaphilones yielded the structure elucidation of six new multiformins E–J (10–15) and the revision of the stereochemistry of the multiformins. Cohaerin and multiformin azaphilones (1–5, 8, 12) were assessed for their activity in a cell-based infection assay. Calu-3 cells expressing human ACE2 receptor showed more than 75% and 50% less infection by SARS-CoV-2 pseudotyped lentivirus particles after treatment with cohaerin C (1) and cohaerin F (4), respectively. Multiformin C (8) and G (12) that nearly abolished the infection of cells. Our data show that multiformin-type azaphilones prevent the binding of SARS-CoV-2 to the cell entry receptor ACE2.

[1]  K. Gunsalus,et al.  Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility , 2021, bioRxiv.

[2]  M. Mehrabi,et al.  Variants in ACE2; potential influences on virus infection and COVID-19 severity , 2021, Infection, Genetics and Evolution.

[3]  Chi‐Huey Wong,et al.  Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection , 2021, Proceedings of the National Academy of Sciences.

[4]  Jared L. Johnson,et al.  Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids , 2020, Nature.

[5]  B. Harris,et al.  Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer’s disease brain , 2020, bioRxiv.

[6]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[7]  Andreas R. Pfenning,et al.  Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates , 2020, Proceedings of the National Academy of Sciences.

[8]  S. Kang,et al.  From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses , 2020, Infection, Genetics and Evolution.

[9]  S. Handu,et al.  Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2 , 2020, Journal of biomolecular structure & dynamics.

[10]  Wei Cheng,et al.  Overview of lethal human coronaviruses , 2020, Signal Transduction and Targeted Therapy.

[11]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[12]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[13]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[14]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[15]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[16]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[17]  Zhènglì Shí,et al.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.

[18]  Leo A. Joyce,et al.  Stereodivergent, Chemoenzymatic Synthesis of Azaphilone Natural Products. , 2019, Journal of the American Chemical Society.

[19]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[20]  V. Corman,et al.  Hosts and Sources of Endemic Human Coronaviruses , 2018, Advances in Virus Research.

[21]  M. Stadler,et al.  Resurrection and emendation of the Hypoxylaceae, recognised from a multigene phylogeny of the Xylariales , 2017, Mycological Progress.

[22]  L. Burrell,et al.  Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation , 2016, Current opinion in nephrology and hypertension.

[23]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.

[24]  M. Stadler,et al.  Cohaerins G-K, azaphilone pigments from Annulohypoxylon cohaerens and absolute stereochemistry of cohaerins C-K. , 2013, Phytochemistry.

[25]  Merlin C. Thomas,et al.  Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. , 2012, Clinical science.

[26]  Yongjun Lu,et al.  Azaphilones and p-terphenyls from the mangrove endophytic fungus Penicillium chermesinum (ZH4-E2) isolated from the South China Sea. , 2011, Journal of natural products.

[27]  F. Beau,et al.  Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. , 2008, Journal of medicinal chemistry.

[28]  T. Hoye,et al.  Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons , 2007, Nature Protocols.

[29]  R. Korstanje,et al.  The emerging role of ACE2 in physiology and disease† , 2007, The Journal of pathology.

[30]  M. Raizada,et al.  ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. , 2006, Physiological genomics.

[31]  M. Stadler,et al.  Antimicrobial azaphilones from the fungus Hypoxylon multiforme. , 2005, Planta medica.

[32]  M. Stadler,et al.  Cohaerins A and B, azaphilones from the fungus Hypoxylon cohaerens, and comparison of HPLC-based metabolite profiles in Hypoxylon sect. Annulata. , 2005, Phytochemistry.

[33]  Julian A. Tanner,et al.  The Severe Acute Respiratory Syndrome (SARS) Coronavirus NTPase/Helicase Belongs to a Distinct Class of 5′ to 3′ Viral Helicases , 2003, Journal of Biological Chemistry.

[34]  James M. Gavin,et al.  Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. , 2002, Journal of the American Chemical Society.

[35]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.